Glonghui December 1: Some investors asked Shuanglu Pharmaceutical (002038.SZ) on the investor interactive platform, “Does the company have oseltamivir and azithromycin-related products?” The company replied that at present, sales of the company's products such as oseltamivir, thymus pentapeptide, and interleukin-2 have increased markedly.
双鹭药业(002038.SZ)：目前奥司他韦、胸腺五肽、白介素-2等产品销量明显增加
Shuanglu Pharmaceutical (002038.SZ): Currently, sales of products such as oseltamivir, thymus pentapeptide, and interleukin-2 have increased markedly
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.